AzTrials
AzTrials

Psoriatic ArthritisPhase 2NCT06176508

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

A Phase 2 study testing HS-10374 and Tofacitinib 5Mg Tab,Oral in people with Psoriatic Arthritis, run by Hansoh BioMedical R&D Company at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Psoriatic Arthritis
What is being tested?
HS-10374 and Tofacitinib 5Mg Tab,Oral
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
160 participants
Where
1 siteChina
Study dates
26 Feb 2024to 28 Aug 2026
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female subjects between the ages of 18-75 years.
  • Has a history of psoriatic arthritis (PsA) for at least 6 months, and meets the Classification Criteria for Psoriatic Arthritis (CASPAR) at screening.
  • Active arthritis as shown ≥ 3 swollen joints (66 joints) and ≥ 3 tender joints (68 joints) at both screening and baseline.
  • Active plague psoriatic skin lesion or documented history of plague psoriatic at screening.
  • hs-CRP ≥ 3mg/L at screening.
  • Subjects either (i) do not have prior exposure to biologics (biologic-naïve) or (ii) have failed or been intolerant to 1 TNF-inhibitor (TNFi-experienced).

Who cannot join

  • Non-plaque psoriasis (ie, guttate, inverse, pustular, erythrodermic or drug-induced psoriasis), with the exception of nail psoriasis, which is allowed.
  • Other autoimmune or autoinflammatory condition ( ie, rheumatoid arthritis, systemic lupus erythematous, gout), with the exception of inflammatory bowel disease and/or autoimmune uveitis being inactive at least 12 months before the screening, as assessed by the investigator.
  • Active fibromyalgia syndrome
  • Recent history of active infection, chronic infection history or risk of serious infection.

Trial locations and contacts

1 site in 1 country.

Hejian Zou, PhD contact

+86-13311881366

hjzou@unirheuma.org

China1 site, 1 recruiting
  • Huashan Hospital affiliated to Fudan University

    Shanghai, Shanghai Municipality, 200040

    Hejian Zou, PhD, (0086)13311881366, hjzou@unirheuma.org

    Recruiting

Other trials in China

About this study

Official title: A Randomized, Double-blind, Placebo- and Comparator-controlled, Multicenter, Phase 2 Trial to Assess the Efficacy and Safety of HS-10374 in Adults With Active Psoriatic Arthritis

This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of active psoriatic arthritis. Additionally, this study is to find the optimal dosing for the future clinical development of HS-10374.

Being tested
HS-10374, HS-10374-matched placebo tablets, Tofacitinib 5Mg Tab,Oral
Keywords
Psoriatic Arthritis
Medical subject headings
Arthritis, Psoriatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • HS-10374Drug

    Administered orally QD for 16 weeks

  • HS-10374-matched placebo tabletsDrug

    Administered orally QD for 16 weeks

  • Tofacitinib 5Mg Tab,OralDrug

    Administered orally BID for 16 weeks

Study groups in NCT06176508
Study groupRoleWhat they receive
HS-10374 Dose 1ExperimentalNot described
Receives: Drug: HS-10374
HS-10374 Dose 2ExperimentalNot described
Receives: Drug: HS-10374
PlaceboPlacebo comparatorNot described
Receives: Drug: HS-10374-matched placebo tablets
tofacitinibActive comparatorNot described
Receives: Drug: Tofacitinib 5Mg Tab,Oral

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 16

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Measured: At week 16

Secondary outcomes (19)
  1. Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 12

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Measured: At week 12

  2. Proportion of participants meeting American College of Rheumatology improvement of 50% (ACR50) response at Week 16

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Measured: At week 16

  3. Proportion of participants meeting American College of Rheumatology improvement of 70% (ACR70) response at Week 16

    The ACR 20, ACR 50 or ACR 70 definition of improvement is a 20%, 50% or 70% improvement, respectively, over baseline in tender and swollen joint counts and a 20%, 50% or 70% improvement, respectively, in 3 of the 5 remaining core data set measures (Subject Global Assessment of disease activity, Physician Global Assessment of psoriatic arthritis, Subject global assessment of pain, HAQ-DI, hs-CRP).

    Measured: At week 16

  4. Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) score at week 16

    The HAQ-DI is a patient-reported outcome measure that assesses the degree of difficulty a subject has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 items. For reach item in the questionnaire the level of activity is cored from 0 to 3 with 0 representing "no difficulty", 1 as "some difficulty", 2 as much "difficulty", and 3 has "unable to do". Any activity that requires assistance from another individual or requires the use of an assistive device adjusts to a score of 2 or more.

    Measured: At week 16

  5. Proportion of participants meeting Psoriasis Area and Severity Index (PASI) 75/90 responses at week 16

    Psoriasis Area and Severity Index (PASI) is a scoring system quantifying the severity of psoriasis based on both lesion severity and area of involvement. PASI assessment is performed by investigators, and the numeric score ranges from 0 to 72, with higher PASI scores denoting more severe disease activity. PASI 75, PASI 90 responses are defined as 75% or 90% improvement in PASI score from baseline.

    Measured: At week 16

  6. Proportion of participants meeting Static physician's global assessment (sPGA) 0/1 score at week 16

    Static physician's global assessment (sPGA) of psoriasis is an average assessment of all psoriatic lesions based on erythema, induration, and scale. It's a 5-point scale performed by investigators. A sPGA score of 0 or 1 means "clear" or "almost clear" respectively.

    Measured: At week 16

  7. Change from baseline in Psoriasis body surface area (BSA) at week 16

    Psoriasis body surface area (BSA) involvement is measured using the handprint method with the size of a patient's handprint representing ~1% of body surface area involved.

    Measured: At week 16

  8. Change from baseline in the dermatology life quality index (DLQI) scores at week 16

    The dermatology life quality index (DLQI) is a patient reported outcome measurement. It's a questionnaire consisting of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. Each question is scored on a scale of 0 to 3, and the sum of each scores range from 0 (no impairment of life quality) to 30 (maximum impairment).

    Measured: At week 16

  9. Change from baseline in Disease Activity Score 28 with C-reactive protein (DAS28-CRP) score at week 16

    DAS28-CRP is a composite outcome measure that assesses: Numbers of joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, except for distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28; Hypersensitive-CRP in the blood to measure the degree of inflammation; Subject Global Assessment of disease activity.

    The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: ≤2.6: Disease remission; 2.6 - 3.2: Low disease activity; 3.2 - 5.1: Moderate disease activity; >5.1: High disease activity.

    Measured: At week 16

  10. Change from baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA) at week 16

    The Disease Activity Index for Psoriatic Arthritis Score (DAPSA) is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count, swollen joint count, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and hs-CRP.

    Measured: At week 16

  11. Proportion of participants meeting Minimal Disease Activity (MDA) response at week 16

    Minimal Disease Activity (MDA) response is defined as a subject fulfilling 5 of 7 of the following outcomes: tender joint count ≤ 1; swollen joint count ≤ 1; PASI ≤ 1 or body surface area (BSA) ≤ 3%; Subject Global Assessment of pain ≤ 15; Subject Global Assessment of disease activity ≤ 20; HAQ-DI ≤ 0.5; Tender entheseal points ≤ 1

    Measured: At week 16

  12. Change from baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) at week 16

    A composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the LEI, the tendor dactylitis count and the hs-CRP.

    Measured: At week 16

  13. Proportion of participants achieving Psoriatic Arthritis Response Criteria (PsARC) at week 16

    The Psoriatic Arthritis Response Criteria (PsARC) consists of 4 measurements: tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of psoriatic arthritis. In order to be classified as a PsARC responder, subjects must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.

    Measured: At week 16

  14. Change from baseline in the Short Form-36 Survey (SF-36) score at week 16

    The SF-36 is a patient-reported outcome measure in clinical practice and research. The instrument includes 36 items to measure the following 8 health dimensions over the past 4 week: 1) limitations in physical activities, such as bathing or dressing; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality; and 8) general health perceptions.

    Measured: At week 16

  15. Change from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score among participants with spondylitis as one of their presentations of PsA at week 16

    Symptoms of spondylitis over the past week will be evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis:

    • Fatigue
    • Spinal pain
    • Joint pain and swelling
    • Areas of localized tenderness
    • Morning stiffness duration
    • Morning stiffness severity A higher count indicates worse disease.

    Measured: At week 16

  16. Change from baseline in dactylitis by Leed's dactylitis index (LDI) at week 16

    Leed's Dactylitis Index (LDI) is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. A higher score indicates worse dactylitis and is based on the current evaluation.

    Measured: At week 16

  17. Change from baseline in enthesitis by Leed's enthesitis index (LEI) at week 16

    The Leed's enthesitis index (LEI) was developed specifically for PsA. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.

    Measured: At week 16

  18. Incidence of adverse events (AEs), serious adverse events (SAEs)

    Measured: Baseline to Week 20

  19. Ctrough of HS-10374

    Trough observed plasma concentration of HS-10374

    Measured: Baseline to Week 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2023
  2. Study start26 Feb 2024
  3. Primary completion28 Apr 2026 (estimated)
  4. Study completion28 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
160 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06176508
Sponsor's protocol ID
HS-10374-202
Status last verified
Jul 2024
First submitted
8 Dec 2023
Last updated
18 Jul 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing HS-10374 and Tofacitinib 5Mg Tab,Oral in people with Psoriatic Arthritis, run by Hansoh BioMedical R&D Company at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Hejian Zou, PhD (+86-13311881366, hjzou@unirheuma.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of participants meeting American College of Rheumatology improvement of 20% (ACR20) response at Week 16 (time frame: At week 16). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in